Key facts
- This page summarizes Jr. Robert E. Funck's Form 4 filing for ABBOTT LABORATORIES (ABT).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 14 May 2024, 17:35.
Jr. Robert E. Funck - 10 May 2024 Form 4 Insider Report for ABBOTT LABORATORIES (ABT)
- Reporting relationship
- EXECUTIVE VICE PRESIDENT
- Issuer ticker
- ABT
- Reported as of
- 10 May 2024
- Net transaction value
- -$581,260
- SEC form
- 4
- Accepted by SEC
- 14 May 2024, 17:35:13 UTC
- Prior SEC filing
- 04 Mar 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Robert E. Funck, Jr. by Jessica H. Paik, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Jr. Robert E. Funck filed Form 4 for ABBOTT LABORATORIES (ABT) on 14 May 2024.
Change
- Previous filing in this sequence was filed on 04 Mar 2024.
- Current net transaction value: -$581,260.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ABT
transaction
Common shares without par value
Options Exercise
- Transaction value
- $474,559
- Shares
- +10,097
- Change %
- +4.8%
- Price
- $47.00
- Shares after
- 221,438
- Date
- 10 May 2024
- Ownership
- Direct
ABT
transaction
Common shares without par value
Sale
- Transaction value
- $1,055,819
- Shares
- -10,097
- Change %
- -4.6%
- Price
- $104.57
- Shares after
- 211,341
- Date
- 10 May 2024
- Ownership
- Direct
- Footnotes
- F1
ABT
holding
Common shares without par value
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 20,000
- Date
- 10 May 2024
- Ownership
- By Trust
- Footnotes
- F2
ABT
holding
Common shares without par value
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 20,000
- Date
- 10 May 2024
- Ownership
- By Trust
- Footnotes
- F2
ABT
holding
Common shares without par value
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 18,765
- Date
- 10 May 2024
- Ownership
- Profit Sharing Trust
- Footnotes
- F3
ABT
holding
Common shares without par value
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 500
- Date
- 10 May 2024
- Ownership
- By Daughter
- Footnotes
- F4
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ABT
transaction
Derivative
Option (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -10,097
- Change %
- -18%
- Price
- $0.000000
- Shares after
- 45,000
- Date
- 10 May 2024
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 10,097
- Exercise price
- $47.00
- Footnotes
- F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.55 to $104.62, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Footnote F2
Held in daughter's annual gift trust. The reporting person disclaims beneficial ownership of all securities held by the trust.
Footnote F3
Balance in the Abbott Laboratories Stock Retirement Trust as of May 10, 2024.
Footnote F4
The reporting person disclaims beneficial ownership of all securities held by his daughter.
Footnote F5
Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.